Welcome to our dedicated page for Insmed news (Ticker: INSM), a resource for investors and traders seeking the latest updates and insights on Insmed stock.
News and press releases about Insmed Incorporated (INSM) provide insight into the company’s progress as a global biopharmaceutical organization focused on serious and rare diseases. Insmed regularly issues updates on its commercial performance, clinical trial milestones, regulatory decisions, and corporate initiatives across its respiratory, immunology & inflammation, and neuro & other rare disease programs.
Recent news has highlighted key events such as U.S. Food and Drug Administration approval of BRINSUPRI (brensocatib) for non-cystic fibrosis bronchiectasis, European Commission approval of BRINSUPRI for specified NCFB patients in the European Union, and detailed business updates around the commercial launch of BRINSUPRI and continued global growth of ARIKAYCE (amikacin liposome inhalation suspension). Investors can also follow announcements on the advancement of TPIP (treprostinil palmitil inhalation powder) into Phase 3 studies for pulmonary hypertension associated with interstitial lung disease and other pulmonary indications.
Insmed’s news flow also covers clinical data readouts from studies such as ASPEN and WILLOW in NCFB, the BiRCh and CEDAR trials evaluating brensocatib in additional neutrophil-mediated diseases, and early-stage developments in gene therapy programs INS1201, INS1202, and INS1203. Corporate communications include financial results, conference presentations at major healthcare and respiratory congresses, and updates on acquisitions such as INS1148, an investigational monoclonal antibody for respiratory and inflammatory conditions.
For followers of INSM stock, this news page offers a centralized view of Insmed’s ongoing commercial execution, regulatory interactions, and pipeline evolution. Regular updates help track how the company’s therapies and investigational candidates are progressing through development and reaching patient populations worldwide.
Insmed (INSM) has announced the redemption of all remaining outstanding 0.75% Convertible Senior Notes Due 2028, totaling $569.5 million. The redemption is scheduled for June 6, 2025, with a redemption price of approximately $1,000.10 per $1,000 principal amount, including accrued and unpaid interest.
Noteholders have the option to convert their notes into common stock until June 4, 2025. The current conversion rate is 30.7692 shares per $1,000 principal amount, equivalent to a conversion price of $32.50 per share. If all notes are converted, up to 17,523,336 shares of common stock will be issued.
Insmed (NASDAQ: INSM) announced the publication of positive Phase 3 ASPEN study results for brensocatib in the New England Journal of Medicine. The landmark study, the largest clinical trial ever conducted in bronchiectasis, demonstrated statistically significant results in treating non-cystic fibrosis bronchiectasis, a chronic inflammatory pulmonary disease.
The study met its primary endpoint with both 10mg and 25mg doses showing reduced annualized exacerbation rates (1.02 and 1.04) compared to placebo (1.29). The 25mg dose notably demonstrated a significant reduction in lung function decline. The drug was well-tolerated, with common side effects including COVID-19, nasopharyngitis, cough, and headache.
Brensocatib is currently under Priority Review with the FDA, with a target action date of August 12, 2025. If approved, it would become the first approved therapy for bronchiectasis and the first approved DPP1 inhibitor.
Insmed (Nasdaq: INSM) has scheduled its first-quarter 2025 financial results release and conference call for Thursday, May 8, 2025. The company will host an investor conference call at 8:00 a.m. ET on the same day to discuss the financial results and provide a business update.
Participants can join via phone by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189. The call will be webcast live on www.insmed.com. A replay will be available until May 15, 2025, through phone and a 90-day webcast archive on the company's website.
Insmed (INSM) will present 11 abstracts at the American Thoracic Society (ATS) 2025 International Conference in San Francisco from May 18-21, 2025. The presentations focus on their respiratory portfolio, featuring new analyses from the Phase 3 ASPEN study of brensocatib in bronchiectasis patients.
Key presentations include:
- Multiple prespecified subgroup analyses examining brensocatib's efficacy and safety
- Post-hoc analysis of lung function changes in bronchiectasis patients
- Health status improvements in patients with Mycobacterium Avium Complex (MAC) lung disease
- Clinical data from Phase 2a study of treprostinil palmitil inhalation powder in pulmonary hypertension
Chief Medical Officer Dr. Martina Flammer emphasized the significance of presenting new subgroup analyses from ASPEN, noting it as the largest Phase 3 clinical trial in bronchiectasis to date, particularly important given no treatments are specifically approved for this condition.
Insmed (INSM) has granted inducement awards to 18 new employees as approved by the company's Compensation Committee under NASDAQ Listing Rule 5635(c)(4). The awards, issued on March 7, 2025, consist of options to purchase 47,960 shares of Insmed common stock at an exercise price of $74.89 per share, matching the closing price on the Nasdaq Global Select Market on the grant date.
The stock options come with a 10-year term and feature a four-year vesting schedule. The vesting terms include 25% of shares vesting on the first anniversary, followed by 12.5% vesting every six months through the fourth anniversary, contingent on continued employment.
Insmed (INSM) announced that the FDA does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib in patients with non-cystic fibrosis bronchiectasis. The FDA has maintained the application under Priority Review with a PDUFA target action date of August 12, 2025.
The NDA is supported by data from the ASPEN study, the largest Phase 3 study ever conducted in bronchiectasis patients. If approved, brensocatib would become the first approved treatment for bronchiectasis and the first in a new class of medicines called dipeptidyl peptidase 1 (DPP1) inhibitors for treating neutrophil-mediated diseases.
Insmed reported its Q4 and full-year 2024 financial results, highlighting a 19% annual growth in ARIKAYCE revenue, totaling $104.4 million for Q4 and $363.7 million for the year, exceeding guidance. The company reiterated its 2025 global ARIKAYCE revenue guidance of $405-$425 million, anticipating double-digit growth. Significant milestones include the FDA's acceptance of the NDA for brensocatib with a PDUFA target date of August 12, 2025. Key clinical trials for TPIP and ARIKAYCE are on track, with topline data expected in mid-2025 and early 2026, respectively.
Insmed ended 2024 with approximately $1.4 billion in cash and equivalents. R&D expenses rose to $179.7 million in Q4 and $598.4 million for the year, driven by increased headcount and stock-based compensation. SG&A expenses also increased significantly to $142.5 million in Q4 and $461.1 million for the year due to preparations for the anticipated U.S. launch of brensocatib. The company reported a net loss of $235.5 million for Q4 and $913.8 million for the full year.
Looking ahead, Insmed plans to invest in the commercialization of ARIKAYCE, the launch of brensocatib, and the advancement of its clinical and pre-clinical programs.
Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its management's upcoming presentations at two major investor conferences in March 2025. The company will present at the 45th Annual TD Cowen Healthcare Conference in Boston on March 3, 2025, at 9:10 a.m. ET, and at the Leerink Partners Global Healthcare Conference in Miami on March 11, 2025, at 8:00 a.m. ET.
Both presentations will be available through live webcasts accessible via the investor relations section of Insmed's website at www.insmed.com. The webcasts will remain archived for 30 days after the events conclude.
Insmed (Nasdaq: INSM) has announced it will release its fourth-quarter and full-year 2024 financial results on Thursday, February 20, 2025. The company will host a conference call for investors at 8:00 a.m. ET on the same day to discuss the results and provide a business update.
Participants can join the call by dialing (888) 210-2654 (U.S.) or (646) 960-0278 (international) using access code 7862189. The call will be webcast live on Insmed's website. A replay will be available until February 27, 2025, through both dial-in and webcast options, with the webcast archived for 90 days on the company's website.
Insmed (INSM) has announced the granting of inducement awards to 66 new employees as approved by its Compensation Committee, in compliance with NASDAQ Listing Rule 5635(c)(4). On February 3, 2025, the employees received options to purchase a total of 108,860 shares of Insmed common stock at an exercise price of $77.88 per share, which was the closing price on the Nasdaq Global Select Market on the grant date.
The stock options come with a 10-year term and a four-year vesting schedule. The vesting terms include 25% of shares vesting on the first anniversary of the grant date, followed by 12.5% vesting every six months through the fourth anniversary, contingent upon continued employment with Insmed.
FAQ
What is the current stock price of Insmed (INSM)?
What is the market cap of Insmed (INSM)?
